<DOC>
	<DOCNO>NCT00853866</DOCNO>
	<brief_summary>The hypothesis study combination reboxetine/tDCS effective enhance motor function daily life ( assessed Jebsen Taylor test ) compare reboxetine tDCS alone . The protocol design within-subject , block randomize placebo-controlled double-blind crossover study .</brief_summary>
	<brief_title>Enhancement Motor Function With Reboxetine Transcranial Direct Current Stimulation</brief_title>
	<detailed_description>One important feature human brain ability undergo plastic change reorganization learn lesion nervous system . This ability major importance treatment functional deficit stroke . Stroke major disease lead persistent functional disability Germany . However , success rate therapeutic intervention , especially chronic stroke patient , still unsatisfactory . Thus , basic science essential discover new therapeutic option bear potential translation clinical practice . Recent evidence point modulate motor cortical excitability order enhance motor function stroke patient . For purpose , reboxetine selective reuptake inhibitor noradrenaline transcranial direct current stimulation proven effective enhance motor function need daily life activity 10-12 % . These improvement significant compare placebo , still clinically unsatisfactory . Thus , protocol aim enhance excitability modulatory effect single intervention combination reboxetine tDCS . The hypothesis study combination reboxetine/tDCS effective enhance motor function daily life ( assessed Jebsen Taylor test ) compare reboxetine tDCS alone . The protocol design within-subject , block randomize placebo-controlled double-blind crossover study . 12 chronic stroke patient persistent functional deficit arm and/or hand include . The primary outcome measure time need fulfill subtests Jebsen Taylor test . All patient undergo four different condition four different session : 1 ) reboxetine + verum tDCS ; 2 ) reboxetine + sham tDCS 3 ) placebo drug + verum tDCS 4 ) placebo drug + sham tDCS .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Reboxetine</mesh_term>
	<criteria>age 18 86 patient contractually capable firstever , ischemic stroke minimum time since stroke 9 month paresis arm/hand muscle 3 MRC scale multiple cerebral lesion associate residual deficit severe head trauma past seizure ferromagnetic implant head/neck region pacemaker psychiatric disorder neurological disease besides stroke intake illegal drug severe aphasia cognitive deficit impede contractual capability contraindication reboxetine ( seizure , glaucoma , prostate hyperplasia urinary retention , cardiac arrhythmia , potential interaction comedication ) pregnancy breastfeed patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>86 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>stroke</keyword>
	<keyword>reboxetine</keyword>
	<keyword>noradrenaline</keyword>
	<keyword>motor cortex</keyword>
	<keyword>transcranial direct current stimulation</keyword>
	<keyword>motor function</keyword>
	<keyword>rehabilitation</keyword>
	<keyword>Jebsen Taylor test</keyword>
</DOC>